Uréia

PreclinicalSmall molecule

UUniversity of Sao Paulo General Hospital

Uréia is one of 5 small molecule programs targeting Burning Mouth Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Burning Mouth SyndromeActive, not recruiting

Burning Mouth SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Burning Mouth Syndrome

#DrugCompanyPhaseTrials

Klonopin

EEngelhard Arzneimittel GmbH & Co.KG

Approved

6 2

Aspercreme Warming

AAveritas Pharma, Inc.

Preclinical

1 3

Valium

Akero Therapeutics

Preclinical

—4

Alpha Lipoic Acid

NNational Center for Complementary and Integrative Health (NCCIH)

Preclinical

2 5

Uréia

UUniversity of Sao Paulo General Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Burning Mouth Syndrome1 trial

The Role of Xerostomia in Burning Mouth Syndrome: Case - Control Study

Completed·UUniversity of Sao Paulo General Hospital·N/A·NCT01754740·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Uréia. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Uréia compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Uréia. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Sao Paulo General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Sao Paulo General Hospital

Uréia

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Burning Mouth Syndrome1 trial

References

Drug Info

Quick Facts

Related News